Three Consecutive Guidance Cuts, a $151M Goodwill Write-Down, and a Loss-Making SCDE That Just Lost Its Anchor Program — The BlueHalo Bet Is Being Marked Down in Real Time

Results vs. Consensus

Sequential and Year-Over-Year Comparison

Quality of the Quarter

Revenue: The 14% sequential decline and 14–16% consensus miss are the headline failure. Management attributed it to "two external issues and one internal issue": (1) the SCAR stop-work/termination; (2) government funding delays and shutdown after-effects pushing orders one-to-two quarters right; and (3) a ~$40M slug of high-margin revenue pushed to Q4 on last-minute shipping/supply-chain issues (a capacity/execution stumble). Underneath, legacy organic +38% and AxS +25% pro-forma YoY show the franchise is still growing strongly versus a year ago — but the sequential reversal in both segments is the new and concerning data point.

Margins / EBITDA: A genuinely mixed read. Adjusted gross margin held at 27% (vs. 40% YoY) — the persistent BlueHalo-mix reset — and adjusted EBITDA was roughly flat sequentially at $44.5M, with margin actually improving to 11% (from 10%) on cost discipline and synergy capture (year-one synergies "largely achieved"). That cost control is the quarter's quiet positive. But the full-year EBITDA guide was cut to $265–285M from the original $300–320M — the first hard reduction to the profitability number, driven by lower revenue, SCAR, and the $40M push.

EPS: The cleanest positive. Non-GAAP EPS of $0.64 more than doubled the $0.30 prior-year Q3 and rose 45% sequentially from $0.44 — evidence that cost management is working even as revenue fell. It still missed the ~$0.69–0.72 consensus. The GAAP $(3.15) loss is the $151M Space goodwill impairment, a non-cash but substantive admission: the acquisition-date value of the acquired Space business was written down ~17% after the SCAR trigger.

Segment Performance

Both segments declined sequentially — the first time that has happened since the combination. The story is no longer "AxS strong, SCDE early"; it is "SCDE breaking and AxS wobbling on timing."

Autonomous Systems (AxS) — $278.7M, −8% QoQ, the Engine Stalled (Temporarily)

AxS still grew 25% pro-forma YoY — UAS (Groups 1–3) up >50%, Precision Strike & Counter-UAS up >21% on Switchblade 600/300 and Titan — but declined 8% sequentially, its first sequential drop. Management attributes the reversal to shutdown-driven funding delays that pushed orders into Q4 and Q1 FY27, not lost demand. The award flow was strong: an $874M FMS IDIQ (UAS + counter-UAS), a $186M task order for the first next-gen Switchblade 300 Block 20 / 600 Block 2 production, a $23M Marine Corps Titan SV order, and a $13M initial P550 LRR award.

Assessment: The AxS demand thesis is intact — the YoY growth and award slate are strong, and the sequential dip is plausibly timing. But a sequential decline in the segment that is supposed to be the dependable engine, in the same quarter the other segment collapses, removes the "at least AxS is steady" anchor that supported the Hold. It is likely transient; it is also exactly the kind of wobble a perfection-priced stock cannot absorb.

Space, Cyber & Directed Energy (SCDE) — $129.3M, −24% QoQ, Loss-Making, Anchor Gone

SCDE fell 24% sequentially and 19% pro-forma YoY, and ran at a loss. Space & Directed Energy revenue declined 14% on the SCAR stop-work (LOCUST kept growing); Cyber & Mission Systems fell 22% on discontinued programs and shutdown delays. The defining event: the U.S. Space Force terminated the SCAR/BADGER contract for convenience after the two sides could not agree on a fixed-price commercial restructuring, triggering the $151M goodwill impairment. Management is pivoting BADGER, LOCUST, laser comms, and the laser gunsight to commercial fixed-price products — but BADGER's recompete is now a FY28 revenue story, not FY27.

Assessment: This is the crux of the downgrade. The segment that justified buying BlueHalo lost its anchor program, is generating losses, and has had its goodwill marked down. Management's commercialization pivot may well be the right long-term strategy — and the demand for the underlying capabilities is real and urgent — but it converts a near-term EBITDA contributor into a multi-year development bet whose payoff is now FY28+. "We'll re-win it as a commercial product in 12–18 months" is a hopeful frame around a contract the customer just canceled.

Key Topics & Management Commentary

Overall Management Tone: Accountable on the quarter, insistent on the long-term, and visibly leaning on demand anecdotes to offset a weak set of numbers. The CEO explicitly took responsibility ("I'm holding myself accountable more than anyone else") and framed the miss as two external issues plus one internal stumble, while pivoting hard to the Iran-conflict demand surge, the record $4.6B award pipeline, and a "record fourth quarter." The retiring CFO's framing — "there's nothing wrong with this year" — captured the posture: management wants the Street to weigh the demand and dismiss the repeated guide cuts as timing. After three cuts, that ask is wearing thin.

1. The Third Consecutive Guide Cut — and the First to EBITDA

"We're adjusting our revenue guidance range to between $1.85 billion and $1.95 billion and adjusted EBITDA to between $265 million and $285 million." — Wahid Nawabi, Chairman, President & CEO

FY26 revenue guidance has now stepped down from $1.9–2.0B (Q4 FY25) effectively to $1.85–1.95B, and EBITDA from the original $300–320M to $265–285M — a ~$35M midpoint reduction in the profitability number management had defended through Q2. Non-GAAP EPS guidance fell to $2.75–3.10 (from $3.40–3.55). Visibility to the (lower) midpoint is 98%.

Assessment: The EBITDA cut is the line that matters. Through Q2, management held EBITDA and asked investors to trust the Q4 ramp; at Q3 it conceded that ramp is smaller. Three consecutive downward revisions establish a pattern, and the move from "EPS-only / tax-driven" cuts to a real EBITDA cut marks a step-change in the deterioration. The pattern, not any single number, is the basis for moving to Underperform.

2. SCAR Terminated and a $151M Goodwill Impairment

"The U.S. Space Force has concluded to terminate our existing contract for convenience… This resulted in a noncash $151 million goodwill impairment… The reevaluation resulted in a reduction in the acquisition-date value of the acquired space business of approximately 17%." — Wahid Nawabi, CEO; Kevin McDonnell, EVP & CFO

Unable to agree on a fixed-price commercial restructuring, the Space Force terminated SCAR for convenience (AV recovers allowable incurred costs plus a fee). The trigger forced a goodwill-impairment test that wrote down the acquired Space business ~17% ($151M). ~$1.5B of unfunded backlog tied to SCAR will be removed.

Assessment: A goodwill impairment is the accounting system formally agreeing that the acquirer's original valuation was too high. Marking down the Space business 17% — less than a year after closing — is a hard, external validation of the SCDE concern we have flagged since Q1. Management's reframe (re-win it as a higher-margin commercial product) is plausible and even strategically sound, but it does not change the fact that the segment's flagship program is gone and its value has been written down.

3. SCDE: From Acquisition Rationale to Loss-Making Drag

"We do not expect the SCAR program to have a significant impact on our growth profile beyond this year… There are several other products and technologies within our Space & Directed Energy business that is in high demand and a transition to commercialization today… LOCUST… directed gunsight… laser communication terminals." — Wahid Nawabi, CEO

SCDE fell 24% sequentially and ran at a loss. Management's forward case rests on commercializing LOCUST (directed energy), the laser-comm terminals, and the laser gunsight, plus BADGER's eventual recompete — all framed as FY27–FY28 growth-and-margin drivers.

Assessment: The pivot to commercial fixed-price products is the right long-term model (it is how AV built Switchblade and Puma), and the underlying demand — especially LOCUST amid the drone-saturated Iran conflict — is genuine. But the segment is now a near-term loss center whose margin inflection has been pushed to FY28 for its biggest piece (BADGER). Investors bought the BlueHalo thesis on SCDE's high-TAM optionality; a year in, that optionality is costing money and its timeline keeps extending.

4. The Demand Is Real: $4.6B in YTD Awards, +38% Legacy Organic, and Iran

"The current conflict in Iran is a reminder that our country and our international allies rely on our defense… capabilities… I just read… that Iran has launched close to 1,400 one-way attack drones into UAE alone in one week. The need for LOCUST, the need for our RF jammers, the Titan series, the need for our one-way attack drones such as Red Dragon… is starting to look better and better." — Wahid Nawabi, CEO

Legacy organic growth was +38%, YTD awards hit a record $4.6B, and the Iran conflict is driving urgent demand across exactly AV's strongest categories (counter-UAS, directed energy, one-way attack, ISR). A Golden Dome limited-area-defense site at Grand Forks AFB is sized at ~$0.5B over three years.

Assessment: This is why the rating is Underperform and not something more severe, and why we are explicit that the franchise is not broken. The demand signals are genuine and large, and AV's "produce at scale today" advantage is real when allies need capability now. But demand has never been the question for AV; converting it to funded revenue and profit on a predictable schedule is — and that is precisely what three guide cuts say it is failing to do.

5. The Commercialization Pivot: Right Strategy, Wrong Timing for the Multiple

"By transitioning these offerings to commercial products, we can quickly scale manufacturing… improve margins and broaden our customer base… This is a recipe that AV has demonstrated successfully several times in its history." — Wahid Nawabi, CEO

Management is converting the BlueHalo development-stage, cost-plus programs (BADGER, LOCUST, laser comms, gunsight) into commercial fixed-price products — taking R&D risk upfront to earn higher product margins later. Year-one synergies were "largely achieved."

Assessment: Strategically coherent and consistent with how AV created its existing franchises. But it is a multi-year transition that defers SCDE's profitability to FY27–FY28, and it is being executed under duress (post-SCAR-termination) rather than from strength. The right strategy on a timeline the current valuation does not allow for is, for a 12-month rating, a reason for caution.

6. AxS: A Sequential Stumble in the Dependable Engine

"Even though the government shutdown in early November caused a delay in funding and shifted the timing of certain orders, revenue for this segment still experienced significant growth compared to the same quarter last year… We expect additional delayed orders… to be booked in the fourth quarter… and first quarter of fiscal year 2027." — Wahid Nawabi, CEO

AxS grew 25% YoY but fell 8% sequentially on shutdown-driven order timing. The award book remained strong (the $874M FMS IDIQ, the first next-gen Switchblade production order, P550 LRR initial), and management is expanding Switchblade capacity (Salt Lake City, $2B+ potential) and Titan production (4x this year, 10x by FY30).

Assessment: The sequential decline is very likely timing, and the YoY growth + award flow argue AxS remains healthy. But the loss of the "AxS is the steady anchor" narrative — even for one quarter, even for defensible reasons — matters when it coincides with the SCDE collapse. It removes the offset that made the prior quarter a Hold rather than worse.

7. Cost Discipline: The Quiet Positive Under the Misses

"Adjusted earnings per diluted share [were] $0.64 for the third quarter… more than double the $0.30 per diluted share for the third quarter of fiscal 2025… Year-to-date, we have largely achieved our expected year-one synergies." — Kevin McDonnell, CFO

Despite the revenue miss, EPS doubled YoY and rose 45% sequentially, adjusted EBITDA margin improved to 11% (from 10%), and SG&A leverage improved (15% of revenue vs. 20% YoY). Year-one synergy targets were met.

Assessment: Genuinely creditable, and it tempers the bear case: AV is managing costs and capturing synergies even as the top line disappoints. It is the strongest argument that the franchise is fundamentally sound and that, if revenue timing normalizes, profitability can follow. It does not, however, offset a third guide cut, an impairment, and a lost anchor program at this valuation.

8. CFO Transition

"Kevin will retire at the end of July… Over this period, AV's market cap increased from approximately $1 billion to over $10 billion." — Wahid Nawabi, CEO

CFO Kevin McDonnell (in the role since 2020) will retire end of July, staying to transition his successor. The departure was framed as long-planned, not abrupt.

Assessment: Not a red flag in isolation — the transition appears orderly and McDonnell oversaw a 10x market-cap increase. But a CFO change during a period of guidance volatility, a major-acquisition integration, and a segment write-down adds a layer of execution and continuity risk precisely when the model most needs steady financial stewardship. Worth monitoring; not, by itself, thesis-changing.

Guidance & Outlook

The revised guide is a genuine reset, not a re-shuffle: the EBITDA midpoint falls ~$35M versus the figure management defended one quarter ago, and revenue, EBITDA, and EPS all step down together. Management frames the year as still a growth year (~12% revenue growth over pro-forma FY25 at the midpoint) with "another record fourth quarter," but the record-Q4 promise is now against a materially lower full-year bar than the one set six months ago.

Implied Q4: With nine-month revenue of ~$1,335M and a $1.90B midpoint, Q4 implies ~$565M — a record, and a steep sequential step from $408M, dependent on the delayed shutdown/appropriations funding finally converting to task orders and the ~$40M of pushed shipments landing. The EBITDA midpoint (~$275M) less ~$135M first nine months implies a large Q4 EBITDA — again the bulk of the year's profit in one quarter.

Street at: Consensus had sat at ~$1.97B revenue / ~$3.31 EPS; the cut pulls estimates down to the new ranges. The bigger effect is on FY27 modeling — with SCAR gone (management says <$100M FY27 impact) and the commercialization timeline extended, the Street must rebuild the SCDE growth-and-margin assumptions that underpinned the bull case.

Guidance style: Confident narrative, repeatedly reset numbers. Management's 98% visibility and "record Q4" framing are meant to reassure, but the credibility of forward guidance is now impaired by three consecutive misses against it. We weight the demonstrated pattern over the stated confidence and assume continued risk of slippage into the Q4/FY27 hand-off.

Analyst Q&A Highlights

SCDE's Growth and Margins Without SCAR

The opening line of questioning went straight to the wound: with SCAR gone — the program management had cited as the segment's EBITDA driver — how should investors think about SCDE growth and margins going forward? Management argued the underlying capability gap is more urgent than ever and pointed to LOCUST, laser comms, and the gunsight as the replacement drivers.

Q: "How should we be thinking about growth at the business moving forward?… SCAR was a pretty big driver of what you guys were expecting to do in EBITDA this year for that segment. What else could be carrying the weight here on out, not just in '26 but beyond?"
— Andre Madrid, BTIG

A: "We do not expect the SCAR program to have a significant impact on our growth profile beyond this year… There are several other products… LOCUST… directed gunsight… laser communication terminals, all of which are expected to grow rapidly over the next 2 to 3 years."
— Wahid Nawabi, CEO

Assessment: Management answered with conviction but no numbers — "other products will carry it" is an assertion, not a bridge. The replacement drivers are real (LOCUST especially), but they are earlier-stage than SCAR was, which means the segment's near-term profitability gets worse before it gets better. The answer reinforces, rather than resolves, the SCDE concern.

The Full-Year Guide-Down Bridge: SCAR vs. Everything Else

A recurring line of questioning pressed for the composition of the ~$75M revenue and ~$35M EBITDA guide cuts — how much was SCAR versus broader volume/mix and the pushed shipments. Management attributed most of the EBITDA reduction to lower revenue (volume), with SCAR a contributor alongside the shutdown delays and capacity constraints.

Q: "If I just look at the midpoint from where you had the FY '26 guide to where you guided now, it's about a $75 million shift down. Is it fair to assume that a strong majority of that is SCAR-related, or more an even split of SCAR and the other programs?"
— Multiple analysts incl. Trevor Walsh, Citizens; Ken Herbert, RBC Capital Markets

A: "Some of it is obviously related to SCAR… most of the EBITDA revised guidance is a result of the lower revenue guidance and somewhat more R&D… we've been somewhat capacity-constrained on the things that… we could have probably shipped this year… it's really the volume that drives down the number."
— Kevin McDonnell, CFO

Assessment: Telling. The cut is "mostly volume," not only SCAR — meaning the shortfall is broader than the one cancelled program, spanning shutdown-delayed orders and self-described capacity constraints. That is a less clean story than "one program went away," and it undercuts the idea that the miss is an isolated, external event. Volume-driven EBITDA cuts are exactly what a perfection multiple cannot absorb.

SCAR Recompete: What Success Looks Like, and When

One exchange pushed on the path forward for SCAR/BADGER — what a successful recompete looks like and when it could contribute revenue again. Management described a commercial-product strategy and, critically, placed meaningful revenue contribution in FY28 rather than FY27.

Q: "Is it conceivable you could be selling this revised product as early as maybe fiscal '27? Or is this more of a longer-term development effort?"
— Jonathan Siegman, Stifel

A: "Most likely… it will be more of a contributor in fiscal year '28 than '27 in terms of significant revenue contribution… There are other items in the space business that's going to contribute revenue, but most likely not the BADGER systems in the next fiscal year."
— Wahid Nawabi, CEO

Assessment: The most consequential timing disclosure of the call. The flagship Space program goes from active revenue to a FY28 contributor — a two-plus-year gap during which AV funds the redevelopment on its own R&D dollars. That is a long time to carry a loss-making segment on the promise of a recompete the customer has not yet structured. It pushes the SCDE payoff well beyond the horizon the current valuation implies.

Does the Iran Conflict Accelerate Demand?

A line of questioning explored whether the active Iran conflict — and the drone-saturated threat environment — pulls forward demand for AV's counter-UAS, directed-energy, and one-way-attack systems. Management was emphatic that it does, citing unprecedented RFQ and ROM-quote activity.

Q: "In the event this war with Iran is drawn out… are there any systems… that could be fielded on an accelerated basis… or be part of this $50 billion emergency reconciliation munitions package?"
— Multiple analysts incl. Jan Engelbrecht, Baird; Louie DiPalma, William Blair

A: "I would highlight a very strong imminent demand for accelerated adoption of our one-way long-range attack drones such as Red Dragon… our Directed Energy Systems called LOCUST, and our Titan series of RF detect and defeat solutions, as well as our reconnaissance drones such as JUMP 20 and P550."
— Wahid Nawabi, CEO

Assessment: The demand catalyst is real and well-aligned with AV's strongest products, and the "produce at scale today" advantage genuinely matters when allies need capability immediately. But this is a FY27+ revenue story by management's own framing ("convert to demand in fiscal '27 and beyond") — it supports the long-term franchise, not the near-term numbers that just got cut. The juxtaposition is the whole quarter: surging demand narrated over receding guidance.

Switchblade 400 / LASSO and Capacity

An exchange probed the Switchblade family's trajectory now that the Switchblade 400 has joined the line, and how capacity scales across the 300/400/600 variants. Management framed near-term demand around the existing 300/600 products with the 400 as a longer-dated LASSO/multi-platform driver.

Q: "Now that you officially have the 400 in the product family, how do we think about capacity on that program?… What's the mix of 300, 400, 600, where is capacity, and how do you see that scaling in the next 6 to 12 months?"
— Ken Herbert, RBC Capital Markets

A: "I continue to see a lot of potential and growth… for Switchblade 300 Block 20 and Switchblade 600 Block 2… Switchblade 400 is purposely developed for the future longer-term growth… that's going to be about a year-plus later based on the program adoption cycles… the mix will shift eventually more towards 400, but not anytime soon."
— Wahid Nawabi, CEO

Assessment: The Switchblade franchise remains the healthiest part of the story — robust 300/600 demand now, a 400-driven LASSO/multi-platform leg later, and a $2B+ Salt Lake City capacity build behind it. This is the durable core that floors the valuation. Notably, even here the incremental driver (400/LASSO) is framed as "a year-plus later" — the now-vs-later gap that recurs across the whole portfolio.

Inventory-Obsolescence Risk Against the Demand Surge

A thoughtful exchange asked how AV balances building inventory ahead of surging demand against the risk of obsolescence in a fast-evolving drone battlespace — pertinent given the deliberate build-ahead-of-orders strategy and the inventory increase that pressured cash.

Q: "How do you balance meeting the current demand surges… with the risk of building excess inventory given the pace of advancements in the space and how quickly some technologies are becoming obsolete?"
— Nicholas Labbadia, UBS

A: "The customers today… will take all the demand that we can build… the products are designed such [that] we can make upgrades… on a modular fashion quite quickly… there is not a lot that the adversary can throw at us that can surprise us."
— Wahid Nawabi, CEO

Assessment: A reasonable answer — modular design and Ukraine-tested iteration speed genuinely mitigate obsolescence risk, and customer pull is strong enough to absorb the build. But the question is well-aimed: AV is deliberately funding working capital ahead of funded orders, and in a quarter where $40M of shipments slipped and revenue missed, the build-ahead strategy adds cash and inventory risk on top of the demand-timing risk. Defensible, but another lever bet on a Q4/FY27 that has to materialize.

What They're NOT Saying

1. A quantified SCDE recovery path: Management asserts other products replace SCAR but provided no segment growth/margin numbers and conceded BADGER is a FY28 story. The segment's near-term loss magnitude and inflection date remain undefined.
2. FY27 guidance or framing: Repeatedly teased ("positioned really well for FY27") but explicitly declined — leaving the Street to rebuild the model around a lost SCAR and a deferred commercialization just as the FY26 ramp failed.
3. The real Q4 bridge: A "record Q4" of ~$565M revenue is implied but not built program-by-program; after three quarters of slippage, the bridge to the year's largest quarter is taken on faith.
4. How much of the $40M push actually lands in Q4: The pushed high-margin shipments are assumed to recover in Q4, but management did not commit to the timing or quantify the margin recovery.
5. The cumulative guide-down accountability: Management framed each cut as timing/external, but never addressed the cumulative credibility cost of three consecutive reductions to a guide set only six months earlier.

Market Reaction

• Pre-print setup: Shares entered the print around ~$227, near the highs, with the market capitalization above $10B — still pricing a successful BlueHalo integration and the back-half profitability ramp despite the Q2 wobble.
• After-hours / next-morning move: A modest after-hours decline (~−2.5% toward ~$224) gave way to heavier selling into the next morning, down ~9% pre-market toward ~$201 — a cumulative ~10–12% drawdown from ~$227 over the 24 hours around the print, as the market digested the third guide cut, the impairment, and the SCDE collapse.

The ~10–12% decline is the market re-rating a stock that had priced perfection against a third consecutive disappointment. Notably, sell-side price targets were trimmed across the board even as headline ratings largely stayed constructive — a "lower the target, keep the faith" pattern that often precedes a more durable de-rating when the operational misses persist. The drop is rational and, in our view, not yet complete: at ~$201 the stock still trades at a growth-premium multiple on a guidance number that has been cut three times, which is the asymmetry the Underperform rating reflects.

Street Perspective

Debate: Is This a Timing Trough or a Structural BlueHalo Problem?

Bull view: The misses are external and temporary — SCAR is one program, the shutdown delayed funding that converts in Q4/Q1, and the $40M shipping push recovers. Legacy organic +38%, a record $4.6B in awards, doubling EPS, and the Iran demand surge prove the franchise is accelerating; FY27 will reaccelerate.

Bear view: Three consecutive cuts, a goodwill impairment, a loss-making segment that lost its anchor, and a sequential decline in both segments are not "timing" — they are evidence that BlueHalo's profitability was overestimated and the integration is harder than sold. The commercialization pivot pushes the payoff to FY28.

Our take: The truth is in between, but the weight has shifted to the bears for a 12-month view. The demand is real (bull) and the near-term profitability is genuinely impaired and repeatedly deferred (bear). At this valuation, "real demand, deferred profit, broken guidance credibility" resolves to Underperform.

Debate: Does the Demand Strength Floor the Stock?

Bull view: A record $4.6B award pipeline, the best-positioned counter-UAS/directed-energy/loitering-munition portfolio in defense, and a live conflict driving urgent orders provide a hard demand floor; any pullback is a buying opportunity.

Bear view: Awards aren't funded revenue, funded revenue isn't recognized revenue, and recognized revenue isn't profit — AV keeps proving that gap is wider and slower than the multiple assumes. A demand floor doesn't justify ~35x cut EBITDA.

Our take: The demand floors the business, not the stock at this price. The franchise is durable and the long-term TAM is real — which is why this is Underperform, not a value-destruction call — but the valuation embeds a profitability trajectory the company has missed three times. The floor is well below the current price.

Debate: Is the Commercialization Pivot Bullish or an Admission?

Bull view: Converting BlueHalo's cost-plus programs to commercial fixed-price products is exactly how AV built its profitable franchises; it trades near-term pain for durable, higher margins and a broader customer base.

Bear view: The pivot is being executed under duress after a customer cancelled the anchor contract; "we'll re-win it commercially in FY28" is a hopeful gloss on losing a program and writing down the business that held it.

Our take: Strategically we lean bull — the commercial model is the right one and AV has executed it before. But for a 12-month rating, a strategy whose payoff is FY28, executed from a position of weakness, while the segment loses money, is not a reason to own the stock today at a premium multiple. Right move, wrong window.

Model Update

Valuation: At ~$201 post-drop (from ~$227) on ~47M shares, market cap is ~$9.4B and EV ~$9.7B. Against the cut FY26 EBITDA midpoint (~$275M) that is ~35x EV/EBITDA, ~5x EV/sales, and ~68x the midpoint FY26E EPS (~$2.93) — still a clear growth-premium multiple, on a number that has now been reduced three times. Even after the ~10–12% drawdown, the stock prices a profitability recovery and an FY27 reacceleration that the company has repeatedly failed to deliver on schedule. Fair-value framing: the durable Switchblade/UAS franchise and the genuine demand backdrop justify a premium to legacy primes, but not ~35x EBITDA while EBITDA guidance is falling and the acquisition is being impaired. We see downside risk to the multiple as the Street rebuilds FY27 around a lost SCAR and a FY28 BADGER recompete; the 12-month risk/reward skews negative.

Thesis Scorecard Post-Earnings

Overall: Thesis broken on the dimensions that drive the rating. The demand and the durable Switchblade/UAS franchise remain genuinely strong — which is why this is Underperform, not worse — but the BlueHalo profitability case has been deferred three times and now partially written off, the anchor Space program is gone, even the core segment declined sequentially, and the valuation has not adjusted to any of it.

Action: Downgrading to Underperform from Hold. This is a valuation-and-credibility call, not a verdict on the franchise: AV has the best demand profile in mid-cap defense, but three consecutive guidance cuts, a $151M goodwill impairment, a loss-making SCDE that lost SCAR, and a sequential decline in AxS — against a ~35x-EBITDA multiple on a number that keeps falling — make the 12-month risk/reward unfavorable. We would return to Hold on (1) a clean Q4 that actually delivers the implied record without a fourth cut, (2) concrete evidence SCDE's losses are narrowing and the commercialization pivot is converting to funded orders, or (3) a de-rating that aligns the multiple with the reset numbers. We would move back to Outperform only once the company re-establishes a track record of meeting — not cutting — its own guidance.